Office-based sclerotherapy for recurrent epistaxis due to hereditary hemorrhagic telangiectasia: a pilot study

被引:22
作者
Boyer, Holly [1 ]
Fernandes, Patricia [1 ]
Duran, Olga [2 ]
Hunter, David [2 ]
Goding, George [1 ]
机构
[1] Univ Minnesota, Dept Otolaryngol Head & Neck Surg, Minneapolis, MN 55455 USA
[2] Univ Minnesota, Dept Radiol, Minneapolis, MN 55455 USA
关键词
epistaxis; hereditary hemorrhagic telangiectasia; sclerotherapy; sodium tetradecyl sulfate; Osler-Weber-Rendu syndrome; ARGON PLASMA COAGULATION; OSLER-WEBER-DISEASE; PULSED DYE-LASER; QUALITY-OF-LIFE; ND-YAG LASER; YOUNGS PROCEDURE; NASAL-MUCOSA; MANAGEMENT; THERAPY; EMBOLIZATION;
D O I
10.1002/alr.20053
中图分类号
R76 [耳鼻咽喉科学];
学科分类号
100213 ;
摘要
Background: The aim of this pilot study is to evaluate office-based sclerotherapy using sodium tetradecyl sulfate (STS) for epistaxis due to hereditary hemorrhagic telangiectasias (HHT). Patients with HHT suffer from unpredictable, recurrent, severe nasal bleeding necessitating emergency care, nasal packing, blood transfusions, and invasive procedures. Methods: In this retrospective study 7 patients with a history of treatment for recurrent epistaxis due to HHT were treated in an office-based setting with intralesional injection of STS. Treatment results were evaluated using a questionnaire. All patients had undergone multiple prior procedures attempting to control epistaxis. Results: Patients had an average of 5 sclerotherapy treatments for HHT. Patients were treated using topical and/or local anesthesia with no reports of discomfort. Bleeding requiring intervention did not occur during the procedures. After the procedure all patients (100%) reported significantly less frequent and less severe nasal bleeding. A total of 83% reported that their need for nasal packing was reduced. All patients were willing to undergo the same treatment again. No complications such as perforation, crusting, or foul smell were reported. Conclusion: This is the first clinical experience demonstrating that office-based sclerotherapy with STS is a safe, tolerable, and useful alternative for the treatment of epistaxis due to HHT. (C) 2011 ARS-AAOA, LLC.
引用
收藏
页码:319 / 323
页数:5
相关论文
共 56 条
[1]  
AASSAR OS, 1991, LARYNGOSCOPE, V101, P977
[2]   Sclerotherapy of craniofacial venous malformations: Complications and results [J].
Berenguer, B ;
Burrows, PE ;
Zurakowski, D ;
Mulliken, JB .
PLASTIC AND RECONSTRUCTIVE SURGERY, 1999, 104 (01) :1-11
[3]   Argon plasma coagulation for the treatment of hereditary hemorrhagic telangiectasia [J].
Bergler, W ;
Riedel, F ;
Baker-Schreyer, A ;
Juncker, C ;
Hörmann, K .
LARYNGOSCOPE, 1999, 109 (01) :15-20
[4]   Topical estrogens combined with argon plasma coagulation in the management of epistaxis in hereditary hemorrhagic telangiectasia [J].
Bergler, W ;
Sadick, H ;
Riedel, F ;
Götte, K ;
Hörmann, K .
ANNALS OF OTOLOGY RHINOLOGY AND LARYNGOLOGY, 2002, 111 (03) :222-228
[5]   ULTRASTRUCTURE AND 3-DIMENSIONAL ORGANIZATION OF THE TELANGIECTASES OF HEREDITARY HEMORRHAGIC TELANGIECTASIA [J].
BRAVERMAN, IM ;
KEH, A ;
JACOBSON, BS .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1990, 95 (04) :422-427
[6]   Use of the microdebrider in selective excision of hereditary hemorrhagic telangiectasia: A new approach [J].
Bublik, Michael ;
Sargi, Zoukaa ;
Casiano, Roy R. .
OTOLARYNGOLOGY-HEAD AND NECK SURGERY, 2007, 137 (01) :157-158
[7]  
Bunke Nisha, 2009, Perspect Vasc Surg Endovasc Ther, V21, P91, DOI 10.1177/1531003509345286
[8]   Hereditary Hemorrhagic Telangiectasia/Avastin [J].
Davidson, Terence M. ;
Olitsky, Scott E. ;
Wei, Julie L. .
LARYNGOSCOPE, 2010, 120 (02) :432-435
[9]  
de Gussem EM, 2009, RHINOLOGY, V47, P85
[10]  
DUCIC Y, 1995, J OTOLARYNGOL, V24, P299